Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Average cost to bring drug candidate to market = US$2.3 Bln

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 15, 2023 10:01pm

131 Views

Post# 35341571

RE:RE:RE:Average cost to bring drug candidate to market = US$2.3 Bln

Correction : And any reference to a 400 patient Phase III clinical trial may also be referencing a Phase 3/4 confirmatory trial that would be planned by ONCY's acquirer and executed AFTER an accelerated approval has been granted in metastatic breast cancer (mBC).

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China